EXHIBIT 99.1

                                 (LUMINEX LOGO)

    LUMINEX CORPORATION NAMES RUSSELL W. BRADLEY AS VICE PRESIDENT, BUSINESS
                       DEVELOPMENT AND STRATEGIC PLANNING

           GREGORY GOSCH AND RANDEL MARFIN ASSUME NEW RESPONSIBILITIES


Austin, TX - May 23, 2005 / PRNewswire-FirstCall / -- Luminex Corporation
(Nasdaq: LMNX), a developer and manufacturer of proprietary life science and
biological testing technologies, today announced that Russell W. Bradley has
been named Vice President, Business Development and Strategic Planning. In this
role, Mr. Bradley will be responsible for all elements of the Company's
strategic partnerships and business development as well as strategic planning.
Mr. Bradley brings over 17 years of industry experience in business development,
strategic marketing and sales management in both the life sciences and
diagnostics markets to Luminex. Mr. Bradley has held a number of positions
during his career, virtually all with Beckman Coulter, Inc. He served most
recently as Director of Beckman Coulter CARES Initiative and previously as
Director of Market and Commercial Development for Beckman Coulter. Mr. Bradley
has a Bachelor of Science degree in Immunology and Biochemistry from Monash
University, Melbourne, Victoria, Australia.

Patrick J. Balthrop, Chief Executive Officer and President of Luminex commented,
"The addition of Russell Bradley to the Luminex management team is a significant
step forward for Luminex. The Company will immediately benefit from Russell's
experience and extensive industry knowledge, and the impact on the Company will
be valuable for years to come. He is the ideal choice to lead the expansion of
our business development efforts and strategies."

Luminex Corporation also announced today two related executive appointments.
Gregory J. Gosch has been named Vice President Marketing and Sales and will
assume responsibility for sales. Randel S. Marfin has been named to the new
position of Vice President, Luminex Bioscience Group, and will assume
responsibility for the development of additional assay and content applications
for partners and laboratory customers on the Luminex instrument platform.

Mr. Balthrop commented, "Luminex is dedicated to providing the ideal solutions
to our partners and customers. These appointments reflect the importance of both
our partner relationships and the role that bioscience application expansion
will play in the Company's future long term."

Luminex Corporation develops, manufactures and markets proprietary biological
testing technologies with applications throughout the life sciences industry.
The Company's xMAP(R) system is an open-architecture, multi-analyte technology
platform that delivers fast, accurate and cost-effective bioassay results to
markets as diverse as pharmaceutical drug discovery, clinical diagnostics and
biomedical research, including the genomics and proteomics research markets. The
Company's xMAP technology is sold worldwide and is in use in leading research
laboratories as well as major pharmaceutical, diagnostic and biotechnology
companies. Further information on Luminex Corporation or xMAP can be obtained on
the Internet at http://www.luminexcorp.com.




Statements made in this release that express Luminex's or management's
intentions, plans, beliefs, expectations or predictions of future events are
forward-looking statements. The words "believe," "expect," "intend," "estimate,"
"anticipate," "will," "could," "should" and similar expressions are intended to
further identify such forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. It is important to note that the
Company's actual results or performance could differ materially from those
anticipated or projected in such forward-looking statements. Factors that could
cause Luminex's actual results or performance to differ materially include risks
and uncertainties relating to, among others, market demand and acceptance of
Luminex's products, the Company's dependence on strategic partners for
development, commercialization and distribution of products, fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle, Luminex's
ability to scale manufacturing operations, potential shortages of components,
competition, the timing of regulatory approvals and any modification of the
Company's operating plan in response to its ongoing evaluation of its business,
as well as the risks discussed under the heading "Risk Factors" in Luminex's
Annual Report on Form 10-K for the year ended December 31, 2004, as filed with
the Securities and Exchange Commission. The forward-looking statements contained
herein represent the judgment of Luminex as of the date of this press release,
and Luminex expressly disclaims any intent, obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements to reflect
any change in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements are based.

Contact:      Harriss T. Currie
              Vice President, Finance
              Chief Financial Officer
              512.219.8020
              hcurrie@luminexcorp.com